StockNews.com Initiates Coverage on NeuroMetrix (NASDAQ:NURO)

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Up 0.7 %

Shares of NASDAQ NURO opened at $4.45 on Friday. The stock has a fifty day simple moving average of $4.39 and a two-hundred day simple moving average of $4.16. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73. The firm has a market cap of $9.17 million, a price-to-earnings ratio of -0.97 and a beta of 1.82.

Institutional Investors Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. GTS Securities LLC bought a new position in NeuroMetrix, Inc. (NASDAQ:NURO) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned 1.12% of NeuroMetrix as of its most recent SEC filing. 19.40% of the stock is owned by institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.